Why MoonLake Immunotherapeutics Stock Is Shooting Higher Today
Portfolio Pulse from Vandana Singh
MoonLake Immunotherapeutics (NASDAQ:MLTX) released positive topline results from its Phase 2 MIRA trial evaluating sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS). Both 120mg and 240mg doses achieved significantly higher response rates than the placebo at week 12. The trial will continue to week 24 with a 4-week safety follow-up.
June 26, 2023 | 12:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MoonLake Immunotherapeutics' positive Phase 2 MIRA trial results for sonelokimab in hidradenitis suppurativa patients led to a 58.5% surge in premarket trading.
The positive results from the Phase 2 MIRA trial indicate that sonelokimab has potential in treating moderate-to-severe hidradenitis suppurativa. This news directly impacts MoonLake Immunotherapeutics as it demonstrates the effectiveness of their product, leading to increased investor confidence and a surge in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100